Here’s why Abbott Labs stock is getting dinged after a strong earnings beat
Abbott Labs delivered a second-quarter earnings beat on Thursday, but the company’s ongoing litigation over its baby formula — plus softer guidance for the current quarter — is dragging down shares. We view the pullback as an opportunity. Revenue for the three months ended June 30 rose 4% year over year to $10.38 billion, slightly […]
Here’s why Abbott Labs stock is getting dinged after a strong earnings beat Read More »